Developing new anti-arrhythmics: Clues from the molecular basis of cardiac ryanodine receptor (RyR2) Ca2+-release channel dysfunction

Current Pharmaceutical Design

Volumn 13, Issue 31, 2007, Pages 3195-3211

  George, Christopher H ^a   Lai, F Anthony ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Arrhythmogenesis; Arrythmia; Calcium release channel; Calcium signalling; Cardiac muscle; Excitation contraction coupling; Ryanodine receptor; Sudden cardiac death

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 2 AMINOETHOXYDIPHENYLBORANE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM ION; CALCIUM SENSITIZER; CALDARET; CARDIOVASCULAR AGENT; CPU 0213; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIGOXIN; EPLERENONE; LEVOSIMENDAN; MCC 135; NORPHENAZONE; OUABAIN; OXIPURINOL; PROCAINAMIDE; PROTEIN KINASE C INHIBITOR; ROTIGAPTIDE; RYANODINE; RYANODINE RECEPTOR 2; SPIRONOLACTONE; SULMAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GENE TRANSFER; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERKALEMIA; MORTALITY; NONHUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REENTRY ARRHYTHMIA; REVIEW; RNA INTERFERENCE; SUDDEN DEATH; VIRAL GENE THERAPY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM SIGNALING; CATECHOLAMINES; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; POLYMORPHISM, GENETIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 36749102543     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782341259     Document Type: Review

References (298)

1. Lopshire JC, Zipes DP. Sudden cardiac death: Better understanding of risks, mechanisms, and treatment. Circulation 2006; 114: 1134-6.
2. Zipes DP, Camm JA, Borgreffe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death- executive summary. J Am Coll Cardiol 2006; 48: 1064-108.
3. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task force on sudden cardiac death, European Society of Cardiology. Europace 2002; 4: 3-18.
4. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98: 2334-51.
5. Moss AJ. MADIT-II and its implications. Eur Heart J 2003; 24: 16-8.
6. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40.
7. AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl I Med 1997; 337: 1576-83.
8. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
9. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
10. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337: 1569-75.
11. Huikuri H, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-82.
12. Jauhar S, Slotwiner DJ. The economics of ICDs. N Engl J Med 2004; 351: 2542-4.
13. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471-80.
14. Franzini-Armstrong C, Jorgensen AO. Structure and development of E-C coupling units in skeletal muscle. Annu Rev Physiol 1994; 56: 509-34.
15. 2+ release channels and their regulation by endogenous effectors. Annu Rev Physiol 1994; 56: 485-508.
16. Meissner G. Molecular regulation of cardiac ryanodine receptor ion channel. Cell Calcium 2004; 35: 621-8.
17. Fill M, Copello JA. Ryanodine receptor calcium release channels. Physiol Rev 2002; 82: 893-922.
18. George CH, Jundi H, Thomas NL, Fry DL, Lai FA. Ryanodine receptors and ventricular arrhythmias: Emerging trends in mutations, mechanisms and therapies. J Mol Cell Cardiol 2007; 42: 34-50.
19. Bers DM. Macromolecular complex regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 2004; 37: 417-29.
20. Williams AJ, West DJ, Sitsapesan R. Light at the end of the tunnel: structures and mechanisms involved in ion translocation in ryanodine receptor channels. Quart Rev Biophys 2001; 34: 61-104.
21. 2+ release channels: Perspectives from recombinant expression systems. Cell Biochem Biophys 2005; 42: 197-222.
22. Tunwell REA, Lai FA. Ryanodine receptor expression in the kidney and a non-excitable kidney epithelial cell. J Biol Chem 1996; 271: 29583-8.
23. Sorrentino V, Volpe P. Ryanodine receptors - how many, where and why. Trends Pharmacol Sci 1993; 14: 98-103.
24. Sorrentino V. Molecular biology of ryanodine receptors. In: Sorrentino V, Ed. Ryanodine receptors. Boca Raton, Florida: CRC Press 1995; 85-100.
25. Marks AR. Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J Mol Cell Cardiol 2001; 33: 615-24.
26. Marks AR, Marx SO, Reiken S., Regulation of ryanodine receptors via macromolecular complexes: A novel role for leucine/isoleucine zippers. Trends Cardiovasc Med 2002; 12: 166-70.
27. Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 2004; 14: 227-34.
28. Benkusky NA, Farrell EF, Valdivia HH. Ryanodine receptor channelopathies. Biochem Biophys Res Commun 2004; 322: 1280-5.
29. Wehrens XHT, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: A critical mediator of heart failure progression. Proc Natl Acad Sci USA 2006; 103: 511-8.
30. Zissimopoulos S, Lai FA. Redox regulation of the ryanodine receptor/ calcium release channel. Biochem Soc Trans 2006; 34: 919-21.
31. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7.
32. 2+ release channel. J Clin Invest 2005; 115: 2033-8.
33. Yano M, Yamamoto T, Ikemoto N, Matsuzaki M. Abnormal ryanodine receptor function in heart failure. Pharmacol Ther 2005; 107: 377-91.
34. Wehrens XHT, Marks AR. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci 2003; 28: 671-8.
35. Wehrens XHT, Marks AR. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Disc 2004; 3: 1-9.
36. Wehrens XHT, Lehnart SE, Marks AR. Ryanodine receptor-targeted anti-arrhythmic therapy. Ann N Y Acad Sci 2005; 1047: 366-75.
37. Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Prac Cardiovasc Med 2006; 3: 43-52.
38. Kontula K, Laitinen P, Lehtonen A, Toivonen L, Viitasalo M, Swan H. Catecholaminergic polymorphic ventricular tachycardia: Recent mechanistic insights. Cardiovasc Res 2005; 67: 379-87.
39. George CH, Thomas NL, Lai FA. Ryanodine receptor dysfunction in arrhythmia and sudden cardiac death. Future Cardiol 2005; 1: 531-41.
40. 2+ release (SO1CR). Proc Natl Acad Sci USA 2004; 101: 13062-7.
41. Lehnart SE, Wehrens XHT, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004; 109: 3208-14.
42. 2+ sensitivity of RyR2 mutations reveals distinct mechanisms of channel dysfunction in sudden cardiac death. Biochem Biophys Res Commun 2005; 331: 231-8.
43. 2+ release in permeabilized cardiomyocytes. Cardiovasc Res 2006; 70: 475-85.
44. Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I, et al. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 2006; 98: 1151-558.
45. Wehrens XHT, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113: 829-40.
46. Yin CC, Lai FA. Intrinsic lattice formation by the ryanodine receptor calcium release channel. Nat Cell Biol 2000; 2: 669-71.
47. Yin CC, Blayney LM, Lai FA. Physical coupling between ryanodine receptor-calcium release channels. J Mol Biol 2005; 349: 538-46.
48. 2+ efflux theory and practice. Prog Biophys Mol Biol 2006; 90: 172-85.
49. 2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res 2002; 91: 1015-22.
50. 2+ sparks in mouse ventricular myocytes. Circ Res 2002; 90: 309-16.
51. 2+ transport. Circ Res 2003; 93: 487-90.
52. 2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6). Circ Res 2004; 94: 487-95.
53. Xiao B, Jiang MT, Zhao M, Yang D, Sutherland C, Lai FA, et al. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart fitilure. Circ Res 2005; 96: 847-55.
54. Xiao B, Zbong G, Obayashi M, Yang D, Chen K, Walsh MP, et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon α-adrenergic stimulation in normal and failing hearts. Biochem J 2006; 396: 7-16.
55. Guo T, Zhang T, Mestril R, Bers DM. Ca/Calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 2006; 99: 398-406.
56. 2+ release channel dysfunction. Circ Res 2006; 98: 88-97.
57. Thomas NL, George CH, Lai FA. Role of ryanodine receptor mutations in cardiopathology: More questions than answers? Biochem Soc Trans 2006; 34: 913-8.
58. Wagenknecht T, Grassucci R, Frank J, Saito A, Inui M, Fleischer S. Three-dimensional architecture of the calcium channel/foot structure of sarcoplasmic reticulum. Nature 1989; 338: 167-70.
59. 2+ release channel at 14Å resolution. J Mol Biol 2005; 345: 427-31.
60. Liu Z, Zhang J, Li P, Chen SR, Wagenknecht T. Three-dimensional reconstruction of the recombinant type 2 ryanodine receptor and localization of its divergent region 1. J Biol Chem 2002; 277: 46712-9.
61. Liu Z, Zhang J, Wang R, Chen SRW, Wagenknecht T. Location of divergent region 2 on the three-dimensional structure of cardiac muscle ryanodine receptor/calcium release channel. J Mol Biol 2004; 338: 533-45.
62. Zhang J, Liu Z, Masumiya H, Wang R, Jiang D, Li F, et al. Three-dimensional localization of divergent region 3 of the ryanodine receptor to the clamp-shaped structures adjacent to the FKBP binding sites. J Biol Chem 2003; 278: 14211-8.
63. Liu Z, Wang R, Zhang J, Chen SRW, Wagenknecht T. Localization of a disease-associated mutation site on the three-dimensional structure of the cardiac ryanodine receptor. J Biol Chem 2005; 280: 37941-7.
64. Ludtke SJ, Serysheva II, Hamilton SL, Chui W. The pore structure of the closed RyR1 channel. Structure 2005; 13: 1203-11.
65. Samso M, Wagenknecht T, Allen PD. Internal structure and visualisation of transmembrane domains of the RyR1 calcium release channel by cryo-EM. Nat Struct Mol Biol 2005; 12: 539-44.
66. Radermacher M, Rao V, Grassucci R, Frank J, Timerman AP, Fleischer S, et al. Cryo-electron microscopy and three-dimensional reconstruction of the calcium release channel/ryanodine receptor from skeletal muscle. J Cell Biol 1994; 127: 411-23.
67. Orlova EV, Serysheva II, van Heel M, Hamilton SL, Chiu W. Two structural configurations of the skeletal muscle calcium release channel. Nat Struct Biol 1996; 3: 547-52.
68. Sharma MR, Jeyakumar LH, Fleischer S, Wagenknecht T. Three dimensional structure of ryanodine receptor isoform three in two conformational. states as visualised by cryo-electron microscopy. J Biol Chem 2000; 275: 9485-91.
69. Sharma MR, Jeyakumar LH, Fleischer S, Wagenknecht T. Three-dimensional visualization of FKBP12.6 binding to an open conformation of cardiac ryanodine receptor. Biophys J 2005; 90: 164-72.
70. 2+ channel regulation. Trends Cardiovasc Mod 2000; 10: 310-6.
71. Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M, et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005; 112: 3633-43.
72. Oda T, Yano M, Yamamoto T, Tokuhisa T, Okuda S, Doi M, et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 2005; 111: 3400-10.
73. 2+ channel regulation. J Biol Chem 2000; 275: 11618-25.
74. Ikemoto N, Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci 2002; 7: D671-83.
75. Yamamoto T, Ikemoto N. Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem Biophys Res Commun 2002; 291: 1102-8.
76. Ferrier GR, Moe GK. Effect of calcium on acetylstrophanthidin-induced transient depolarisations in canine Purkinje tissue. Circ Res 1973; 33: 508-15.
77. Lederer WJ, Tsien RW. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibres. J Physiol 1976; 263: 73-100.
78. Rosen MR, Gelband H, Merker C, Hoffman BF. Mechanisms of digitalis toxicity: Effects of oubain on phase four of canine Purkinje fiber transmembrane potential. Circulation 1973; 47: 681-9.
79. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia- insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006; 99: 292-8.
80. Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Subeena S, et al. Mice with R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci USA 2006; 32: 12179-84.
81. Lehnart SE, Terrenoire C, Reiken S, Wehrens XHT, Song LS, Tillman EJ, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci USA 2006; 103: 7906-10.
82. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 2004; 14: 61-6.
83. Cerrone M, Colombi B, Santoro M, Raffale di Barletta M, Scelsi M, Villani L, et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor (RyR2). Circ Res 2005; 96: E77-82.
84. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006; 116: 2510-20.
85. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91: E21-6.
86. Bers DM. Excitation-contraction coupling and contractile force. 2nd ed: Kluwer Academic Publishers 2001.
87. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini A, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111: 869-76.
88. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994; 75: 401-9.
89. 2+ exchange: Cardiac specific knockout of NCX1. Circ Res 2004; 95: 604-11.
90. 2+ flux. Circ Res 2005; 97: 1288-95.
91. Brouillette J, Rivard K, Lizotte E, Fiset C. Sex and strain differences in adult mouse cardiac repolarization: Importance of androgens. Cardiovasc Res 2005; 65: 148-57.
92. Xin HB, Senbonmatsu T, Cheng DS, Wang YX, Copello JA, Ji GJ, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 2002; 416: 334-7.
93. 2+ transient amplitude in adult ventricular myocytes. Circ Res 2006; 98: 1299-305.
94. 2+-handling proteins and heart failure: Novel molecular targets? Curr Med Chem 2003; 10: 967-81.
95. Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol Heart Circ Physiol 1990; 258: H1796-805.
96. Lappi MD, Billman GE. Effect of ryanodine on ventricular fibrillation induced by myocardial ischaemia. Cardiovasc Res 1993; 27: 2152-9.
97. Thandroyen FT, Morris AC, Hagler HK, Ziman B, Pai L, Willerson JT, et al. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res 1991; 69: 810-9.
98. Kusuoka H, Jacobus WE, Marban E. Calcium oscillations in digitalis-induced ventricular fibrillation: Pathogenic role and metabolic consequences in isolated ferret hearts. Circ Res 1988; 62: 609-19.
99. Merillat J, Lakatta EG, Hano O, Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 1990; 67: 1115-23.
100. Kaneko N. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac death and intracellular calcium blocking action. Drug Develop Res 1994; 33: 429-38.
101. Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 1999; 79: 275-81.
102. Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts. Br J Pharmacol 2000; 131: 1363-72.
103. Inagaki K, Kihara Y, Hayashida W, Izumi T, Iwanaga Y, Yoneda T, et al. Anti-ischemic effects of a novel cardioprotective agent, JTV519, is mediated through specific activation of delta-isoform of protein kinase C in rat ventricular myocardium. Circulation 2000; 101: 797-804.
104. Loughrey CM, Smith GL. The effect of K201 (JTV519) on calcium waves in adult rabbit ventricular cardiomyocytes over-expressing FK506-binding protein 12.6 (FKBP12.6). Biophys J 2006; Suppl S: 221a.
105. Dodge-Kafka KL, Kapiloff MS. The mAKAP signalling complex: Integration of cAMP, calcium and MAP kinase signalling pathways. Eur J Cell Biol 2006; 85: 593-602.
106. 2+ release in heart failure. Cardiovasc Res 2000; 48: 323-31.
107. Huang F, Shan J, Reiken S, Wehrens XHT, Marks AR. Analysis of calstabin 2 (FKBP12.6)-ryanodine receptor interactions: Rescue of heart failure by calstabin2 in mice. Proc Natl Acad Sci USA 2006; 103: 3456-61.
108. Kohno M, Yano M, Kobayashi S, Doi M, Oda T, Tokuhisa T, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003; 284: H1035-42.
109. Vest JA, Wehrens XHT, Reiken SR, Lehnart SE, Dobrev DD, Chandra P, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005; 111: 2025-32.
110. Wehrens XHT, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin 2. Science 2004; 304: 292-6.
111. Wehrens XHT, Lehnart SE, Reiken SR, van der Nagel R, Morales R, Sun J, et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci USA 2005; 102: 9607-12.
112. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, et al. FKBP12.6-mediated stabilization of calcium release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003; 107: 477-84.
113. Reiken S, Lacampagne A, Zhou H, Kherani A, Lehnart SE, Ward C, et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: Defective regulation in heart failure. J Cell Biol 2003; 160: 919-28.
114. Lisy O, Burnett JC. New cardioprotective agent K201 is natriuretic and glomemlar filtration rate enhancing. Circulation 2006; 113: 246-51.
115. Feng W, Liu G, Allen PD, Pessah IN. Transmembrane redox sensor of ryanodine receptor complex. J Biol Chem 2000; 275: 35902-7.
116. 2 sensor and NO signaling functions. Cell 2000; 102: 499-509.
117. Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006; 71: 310-21.
118. Meissner G. NADH, a new player in the cardiac ryanodine receptor. Circ Res 2004; 94: 418-9.
119. Xu L, Eu JP, Meissner G, Stamiler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998; 279: 234-7.
120. Edaravone Acute Infarction Study Group. Effect of a novel free scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-9.
121. Freudenberger RS, Schwarz RPJ, Brown J, Moore A, Mann D, Givertz MM, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs 2004; 13: 1509-16.
122. Dulhunty AF, Cengia L, Young J, Pace SM, Harvey PJ, Lamb GD, et al. Functional implications of modifying RyR-activating peptides for membrane permeability. Br J Pharmacol 2005; 144: 743-54.
123. George CH, Jundi H, Thomas NL, Scoote M, Walters N, Williams AJ, et al. Ryanodine receptor regulation by intramolecular interaction between cytoplasmic and transmembrane domains. Mol Biol Cell 2004; 15: 2627-38.
124. 2+ signaling using recombinant fragments of the human cardiac ryanodine receptor (RyR2). Biophys J 2007; Suppl S: 260a.
125. 2+ release channel dysfunction. Biophys J 2007; Suppl S: 262a.
126. Sato Y, Ferguson DG, Sako H, Dorn GW, Kadambi VJ, Yatani A, et al. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 1998; 273: 28470-7.
127. Terentyev D, Cala SE, Houle TD, Viatchenko-Karpinski S, Gyorke I, Terentyeva R, et al. Triadin overexpression stimulates excitation-contraction coupling and increases predisposition to cellular arrhythmia in cardiac myocytes. Circ Res 2005; 96: 651-8.
128. Hong CS, Cho MC, Kwak YG, Song CH, Lee YH, Lim JS, et al. Cardiac remodelling and atrial fibrillation in transgenic mice over-expressing junctin. FASEB J 2002; 16: 1310-2.
129. 2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 2004; 109: 1898-903.
130. Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 2005; 105: 211-8.
131. Harrap SB, Petrou S. Utility of genetic approaches to common cardiovascular disease. Am J Physiol Heart Circ Physiol 2001; 281: H1-6.
132. Bader M, Bohnemeier H, Zollmann FS, Lockley-Jones OE, Ganten D. Transgenic animals in cardiovascular disease research. Exp Physiol 2000; 85: 713-31.
133. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000; 101: 365-76.
134. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem 2003; 278: 51693-702.
135. 2+ leak from the sarcoplasmic reticulum and increases contractilility. Circ Res 2001; 88: 188-94.
136. Loughrey CM, Seidler T, Miller SLW, Prestle J, MacEachern KE, Reynolds DF, et al. Over-expression of FK506-binding protein FKBP12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes. J Physiol 2004; 556: 919-34.
137. George CH, Sorathia R, Bertrand BMA, Lai FA. In situ modulation of the human cardiac ryanodine receptor (hRyR2) by FKBP12.6. Biochem J 2003; 370: 579-89.
138. Park K-S, Mohaptra DP, Misonou H, Trimmer JS. Graded regulation of the Kv2.1 potassium channel by variable phosphorylation. Science 2006; 313: 976-9.
139. 2+/ calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004; 94: E61-70.
140. Zhong G-F, Xiao B-L, Chen SRW. Molecular basis and functional significance of CaMKII phosphorylation of the cardiac calcium release channel (ryanodine receptor, RyR2). Biophys J 2006; Suppl S: 390a.
141. Currie S, Loughrey CM, Craig MA, Smith GL. Calcium/calmodulin-dependent protein kinase IIdelta associates with the ryanodine receptor complex and regulates channel function in rabbit heart. Biochem J 2004; 377: 357-66.
142. Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, et al. Phosphorylation-dependent regulation of ryanodine receptors: A novel role for leucine-isoleucine zippers. J Cell Biol 2001; 154: 699-708.
143. Bers DM. Cardiac ryanodine receptor phosphorylation: Target sites and functional consequences. Biochem J 2006; 396: E1-3.
144. Anderson ME. Calmodulin kinase signaling in the heart: An intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharm Ther 2005; 106: 39-55.
145. 2+/calmodulin kinase signaling pathway. Circ Res 2004; 95: 798-806.
146. Zhang R, Khoo MSC, Wu Y, Yang Y, Grueter CE, Ni G, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005; 11: 409-17.
147. Khoo MSC, Li J, Singh MV, Yang Y, Kannankeril PJ, Wu Y, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006; 114: 1352-9.
148. Kockskamper J, Pieske B. Phosphorylation of the cardiac ryanodine receptor by CW/Calmodulin-dependent protein kinase II: The dominating twin of protein kinase A. Circ Res 2006; 99: 333-5.
149. 2+ current facilitation. J Mol Cell Cardiol 2007; 42: 196-205.
150. 2+ channel facilitation mediated by phosphorylation of the β-subunit by CaMKII. Mol Cell 2006; 23: 641-50.
151. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 2004; 63: 476-86.
152. Litwin SE. "Ryanogate": Who leaked the calcium? Circ Res 2006; 98: 165-8.
153. Wu Y, Roden DM, Anderson ME. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 1999; 84: 906-12.
154. Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 2002; 106: 1288-93.
155. + currents. Circ Res 2006; 99: 1092-9.
156. Maier LS, Bers DM. Calcium, calmodulin, and calcium-calmodulin kinase II: Heartbeat to heartbeat and beyond. J Mol Cell Cardiol 2002; 34: 919-39.
157. 2+ leak in heart failure. Circ Res 2005; 97: 1314-22.
158. Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, et al. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res 2006; 98: 235-44.
159. 2+ handling. Cite Res 2003; 92: 904-11.
160. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 99: 66-70.
161. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28.
162. Sememiuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD, Duff HJ. Time-dependent systolic and diastolic function in mice overexpressing calcineurin. Am J Physiol. Heart Circ Physiol. 2003; 284: H425-30.
163. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-54.
164. Reither G, Schaefer M, Lipp P. PKC-alpha: A versatile key for decoding the cellular calcium toolkit. J Cell Biol 2006; 174: 521-33.
165. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 2006; 20: E346-56.
166. Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvey RD, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123: 25-35.
167. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-23.
168. Poelzing S, Forleo C, Samodell M, Dudash L, Sorrentino S, Anaclerio M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 2006; 114: 368-75.
169. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 2005; 112: 1251-8.
170. Viswanathan PC, Benson DW, Balser JR. A common SCN5A polymorphism modulates the biophysical effects of SCN5A mutation. J Clin Invest 2003; 111: 341-6.
171. Priori SG, Napolitano C. Molecular underpinning of "good luck". Circulation 2006; 114: 360-2.
172. Wong CW, Christen T, Roth I, Chadjichristos CE, Derouette JP, Fogha BF, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med 2006; 12: 950-4.
173. Milting H, Lukas N, Klauke B, Korfer R, Perrot A, Osterziel KJ, et al. Composite polymorphisms in the ryanodine receptor 2 gene associated with arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res 2006; 71: 496-505.
174. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-94.
175. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorpbic ventricular tachycardia. Circulation 2001; 103: 485-90.
176. Kashiwakura Y, Cho HC, Barth AS, Azene E, Marban E. Gene transfer of a synthetic pacemaker channel into the heart: A novel strategy for biological pacing. Circulation 2006; 114: 1682-6.
177. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006; 12: 1256-8.
178. Isner JM. Myocardial gene therapy. Nature 2002; 415: 234-9.
179. Zimmermann WH, Melynchenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006; 12: 452-8.
180. Nam G-B, Burashnikov A, Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005; 111: 2727-33.
181. Katra RP, Laurita KR. Cellular mechanism of calcium-mediated triggered activity in the heart. Circ Res 2005; 96: 535-42.
182. Ennis IL, Li RA, Murphy AM, Marban E, Nuss HB. Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. J Clin Invest 2002; 109: 393-400.
183. Williams ML, Koch WJ. Viral-based myocardial gene therapy approches to alter cardiac function. Annu Rev Physiol 2004; 66: 49-75.
184. Ryther RCC, Flynt AS, Phillips III JA, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12: 5-11.
185. Viatchenko-Karpinski S, Terentyev D, Gyorke I, Terentyeva R, Volpe P, Priori SG, et al. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ Res 2004; 94: 471-7.
186. 2+- activated signaling. Science 2006; 314: 615-20.
187. Ca channels. Circ Res 2005; 97: 1270-9.
188. 2+ content after depletion. Circ Res 1997; 81: 477-84.
189. 2+-dependent reduction of IK1 in rat ventricular cells: A novel paradigm for arrhythmia in heart failure. Cardiovasc Res 2005; 73: 376-85.
190. Kafiluddi R, Kennedy RH, Seifen E. Effects of ryanodine on inotropic and arrhythmogenic actions of cardiotonic steroids. Eur J Pharmacol 1986; 131: 273-8.
191. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophys 2005; 16: 162-6.
192. Billman GE. Effect of calcium channel antagonism on susceptibility to sudden cardiac death: Protection from ventricular fibrillation. J Pharmacol Exp Ther 1989; 248: 1334-42.
193. Billman GE. The calcium channel antagonist, flunarizine, protects against ventricular fibrillation. Eur J Pharmacol 1992; 212: 231-5.
194. Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004; 62: 287-98.
195. Clarke TC, Thomas D, Petersen JS, Evans WH, Martin PE. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol 2006; 147: 486-95.
196. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac contraction. Circulation 2003; 108: 3157-63.
197. Hennan JK, Swillo RE, Morgan GE, Keith JC, Schaub RG, Smith RP, et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 2006; 317: 236-43.
198. Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK, et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Pharmacol 2005; 16; 537-45.
199. Goodenough DA, Paul DL. Beyond the gap: Functions of impaired connexon hemichannels. Nat Rev Mol Cell Biol 2003; 4: 1-10.
200. Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 2006; 397: 1-14.
201. Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. Science 2006; 312: 924-7.
202. Bai D, del Corsso C, Srinivas M, Spray DC. Block of specific gap junction channel subtypes by 2-aminoethoxydiphenyl borate (2-APB). J Pharmacol Exp Ther 2006; 319: 1452-8.
203. 2+ signalling and the generation of arrhythmia in rat atrial myocytes. J Physiol 2002; 541: 395-409.
204. 2+ signalling in cat atrial excitation-contraction coupling and arrhythmias. J Physiol 2004; 555: 607-15.
205. 3) receptor type 2 deficient mice. Circ Res 2005; 96: 1274-81.
206. Bootman MD, Higazi DR, Coombes S, Roderick HL. Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes. J Cell Sci 2006; 119: 3915-25.
207. Proven A, Roderick HL, Conway SJ, Berridge MJ, Horton JK, Capper SJ, et al. Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. J Cell Sci 2006; 119: 3363-75.
208. 2+ release via activation Of IP3 receptors in isolated rat gastric myocytes. J Physiol 2002; 542: 725-33.
209. George CH, Higgs GV, Mackrill JJ, Lai FA. Dysregulated ryanodine receptors mediate cellular toxicity: Restoration of normal phenotype by FKBP12.6. J Biol Chem 2003; 278: 28856-64.
210. Kiselyov K, Xu X, Mozhayeva G, Kuo T, Pessah I, Mignery G, et al. Functional interaction between InsP3 receptors and store-operated Htrp3 channels. Nature 1998; 396: 478-82.
211. 3 receptors. Science 2006; 313: 229-33.
212. i and underlies distributed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 2003; 15: 1015-24.
213. Murphy E, Eisner DA. How does endothelin-1 cause a sustained increase in intracellular sodium and calcium which lead to hypertrophy? J Mol Cell Cardiol 2006; 41: 782-4.
214. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
215. + exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol 1996; 317: 309-16.
216. Ayoub IM, Kolarova J, Yi Z, Trevedi A, Deshmukh H, Lubell DL, et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: Beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitibility. Circulation 2003; 107: 1804-9.
217. Gazmuri RJ, Ayoub IM, Hoffner E, Kolarova JD. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001; 104: 234-9.
218. Paterson DJ. Antiarrhythmic mechanisms during exercise. J Appl Physiol 1996; 80: 1853-62.
219. 2+ exchange inhibitor, KB-R7943 on ouabain-induced arrhythmias in guinea pigs. Br J Pharmacol 1999; 127: 1846-50.
220. 2+ exchange inhibitor, does not suppress ischemia/reperfusion arrhythmias nor digitalis arrhythmias in dogs. Jpn J Pharmacol 2002; 90: 229-35.
221. 2+ overload in rat ventricular myocytes. Circulation 2000; 101: 1441-6.
222. Bar FW, Tzivoni D, Dirksen MT, Fernandez-Ortiz A, Heyndrickx GR, Brachmann J, et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: The randomized multicentre CASTEMI study. Eur Heart J 2006; 27: 2516-23.
223. Reiken S, Wehrens XHT, Vest JA, Barbone A, Klotz S, Mancini D, et al. β-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003; 107: 2459-66.
224. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74.
225. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6 mediated stabilization of ryanodine receptor. Circulation 2002; 105: 1374-9.
226. Swan H, Laitinen P. Familial polymorphic ventricular tachycardia-intracellular calcium channel disorder. Cardiac Electrophys Rev 2002; 6: 81-7.
227. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross Jr. J, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998; 95: 7000-5.
228. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac β-ARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 2001; 98: 5809-14.
229. Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β1-adrenergic but locally confined β2-adrenergic receptor-mediated signaling. Circ Res 2006; 99: 1084-91.
230. Reiken S, Gaburjakova M, Gaburjakova J, He KL, Prieto A, Becker E, et al. β-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 2001; 104: 2843-8.
231. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N, et al. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol 2002; 40: 341-9.
232. Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American.College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 2005; 7: 937-9.
233. Baltogiannis GG, Tsalikakis DG, Mitsi AC, Hatzistergos KE, Elaiopoulos D, Fotiadis DI, et al. Endothetin receptor A blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovasc Res 2005; 67: 647-54.
234. Crockett TR, Scott GA, McGowan NW, Kane KA, Wainwright CL. Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur J Pharmacol 2001; 432: 71-7.
235. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB209670. J Pharmacol Exp Ther 2000; 292: 449-59.
236. Lopez-Valverde V, Anderson CU, Laursen BE, Mulvaney MJ, Simonsen U. Glibenclamide reveals role for endothelin in hypoxia-induced vasoconstriction in rat intrapulmonary arteries. J Cardiovasc Pharmacol 2005; 46: 422-9.
237. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47: 729-35.
238. Okuda S, Yano M, Doi M, Oda T, Tokuhisa T, Kohno M, et al. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure. Circulation 2004; 109: 911-9.
239. Landmesser U, Drexler H. Chronic heart failure: An overview of conventional treatment versus novel approaches. Nat Clin Prac Cardiovasc Med 2005; 2: 628-38.
240. 2+ leak induced by oxidative stress. Circ J 2006; 70: 777-86.
241. Exil VJ, Roberts RL, Sims H, McLaughlin JE, Malkin RA, Gardner CD, et al. Very-long-chain acyl co-enzyme A dehydrogenase deficiency in mice. Circ Res 2003; 93: 448-55.
242. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200.
243. Norgaard A, Botker HE, Klitgaard NA, Toft P. Digitalis enhances exercise-induced hyperkalaemia. Eur J Clin Pharmacol 1991; 41: 609-11.
244. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, et al. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 2001; 3: 165-71.
245. Fridman AI, Matveev SA, Agalakova NI, Fedorova OV, Lakatta EG, Bagrov AY. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertension 2002; 20: 1189-94.
246. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci USA 2001; 98: 13420-4.
247. 2+ release channels: A possible role in cardiac inotropy. Br J Pharmacol 1993; 108: 1043-50.
248. Sagawa T, Sagawa K, Kelly JE, Tsushima RG, Wasserstrom JA. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 2002; 282: H1118-26.
249. Woolcott OO, Gustafsson AJ, Dzabic M, Pietro C, Tedeschi P, Sandgren J, et al. Arachidonic acid is a physiological activator of the ryanodine receptor in pancreatic B-cells. Cell Calcium 2006; 39: 529-37.
250. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
251. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
252. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-4.
253. George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003; 93: 531-40.
254. Zhang J, Hupfeld CJ, Taylor SS, Olefsky JM, Tsien RY. Insulin disrupts β-adrenergic signalling to protein kinase A in adipocytes. Nature 2005; 437: 569-73.
255. Houser SR, Piacentino V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000; 32: 1595-607.
256. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med 2000; 6: 1221-7.
257. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure, JAMA 2003; 289: 871-8.
258. Beiser GD, Epstein SE, Stamper M, Robinson B, Brauwald E. XVII. Effects of ousbain on the haemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm. N Engl J Med 1968; 278: 131-7.
259. Periasamy M. Adenoviral-mediated SERCA gene transfer into cardiac myocytes: How much is too much? Circ Res 2001; 88: 373-5.
260. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308-11.
261. 2+-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424-9.
262. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajar R. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105: 904-7.
263. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864-71.
264. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-15.
265. Venetucci LA, Trafford AW, Eisner DA. Increasing ryanodine receptor open probability alone does not produce arrhythmogenic calcium waves- threshold sarcoplasmic reticulum calcium content is required. Circ Res 2007; 100: 105-11.
266. 2+-release channel by analogues of sulmazole. Br J Pharmacol 1994; 111: 1212-20.
267. Scoote M, George CH, Lai FA, Williams AJ. Characterisation of the human recombinant cardiac intracellular calcium release channel (ryanodine receptor). Biophys J 2004; 86: 402a.
268. Ashcroft FM. From molecule to malady. Nature 2006; 440: 440-7.
269. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569-80.
270. Marban E. Cardiac channelopathies. Nature 2002; 415: 213-8.
271. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri H. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006; 114: 1462-7.
272. Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation. Circulation 2006; 114: 1140-5.
273. Aizawa Y, Ueda K, Komura S, Washizuka T, Chinushi M, Inagaki N, et al. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia. Int J Cardiol 2005; 99: 343-5.
274. Hseuh C-H, Weng Y-C, Chen C-Y, Lin T-K, Lin Y-H, Lai L-P, Lin J-L. A novel mutation (Arg169Gln) of the cardiac ryanodine receptor gene causing exercise-induced bidirectional ventricular tachycardia. Int J Cardiol 2006; 108: 276-8.
275. Tester DJ, Kopplin LJ, Creighton W, Burke AP, Ackerman MJ. Pathogenesis of unexplained drowning: New insights from a molecular autopsy. Mayo Clin Proc 2005; 80: 596-600.
276. d'Amati G, Bagattin A, Bauce B, Rampazzo A, Autore C, Basso C, et al. Juvenile sudden death in a family with polymorphic ventricular arrhythmias caused by novel RyR2 gene mutation: Evidence of specific morphological substrates. Hum Pathol 2005; 36: 761-7.
277. Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC, et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardiac genetic testing. Heart Rhythm 2006; 3: 800-5.
278. Laitinen PJ, Swan H, Kontula K. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: Identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet 2003; 11: 888-91.
279. Creighton W, Virmani R, Kutys R, Burke A. Identification of novel missense mutations of cardiac ryanodine receptor gene in exercise-induced sudden death at autopsy. J Mol Diag 2006; 8: 62-7.
280. Bagattin A, Veronese C, Bauce B, Wuyts W, Settimo L, Nava A, et al. Denaturing HPLC-based approach for detecting RyR2 mutations involved in malignant arrhythinias. Clin Chem 2004; 50: 1148-55.
281. Allouis M, Probst V, Jaafar P, Schott JJ, Le Marec H. Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation. Am J Cardiol 2005; 95: 700-2.
282. Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: A molecular autopsy of 49 medical examiner/ coroner's cases. Mayo Clin Proc 2004; 79: 1380-4.
283. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 2004; 110: 2119-24.
284. Postma. AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RyR2 mutations, bradycardia, and follow up of patients. J Med Genet 2005; 42: 863-70.
285. Tester DJ, Kopplin LJ, Will ML, Ackerman MJ. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm 2005; 2: 1099-105.
286. Aizawa Y, Mitsuma W, Ikrar T, Komura S, Hanawa H, Miyajima S, et al. Human cardiac ryanodine receptor mutations in ion channel disorders in Japan. Int J Cardiol 2007; 116: 263-5.
287. CAST Investigators. Preliminery report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
288. CAST Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33.
289. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH. Preliminery results of the Cardiac Arrest Study Hambury (CASH). Am J Cardiol 1993; 72: 109F-13F.
290. Scoote M, Williams AJ. Myocardial calcium signalling and arrhythmia pathogenesis. Biochem. Biophys Res Commun 2004; 322: 1286-309.
291. Zaccolo M. Use of chimeric fluorescent proteins and fluorescence resonance energy transfer to monitor cellular responses. Circ Res 2004; 94: 866-73.
292. 2+ based on green fluorescent proteins and calmodulin. Nature 1997; 388: 882-7.
293. Remus TP, Zima AV, Bossuyt J, Bare DJ, Martin JL, Blatter LA, et al. Biosensors to measure inositol 1,4,5-trisphosphate concentration in living cells with spatiotemporal resolution. J Biol Chem 2006; 281: 608-16.
294. George CH, Yeung WY, Walters N, Thomas NL, Claycomb WC, Lai FA. A novel cardiomyocyte FRET-based bioassay for investigating the molecular basis of RyR2 dysfunction in arrhythmogenesis. Biophys J 2006: 264a.
295. 2+ indicator GCaMP2. Proc Natl Acad Sci USA 2006; 103: 4753-8.
296. Disanto ME. Contractile mechanisms in diabetes-related erectile dysfunction. Curr Pharm Des 2005; 11(31):3995-4010.
297. Doering CJ, Zamponi GW. Molecular pharmacology of non-L-type calcium channels. Curr Pharm Des 2005; 11 (15): 1887-98.
298. White E. Mechanosensitive channels: Therapeutic targets in the myocardium? Curr Pharm Des 2006; 12(28): 3645-63.